Catalog No.: PC-22258Not For Human Use, Lab Use Only.
PF-07817883 (Ibuzatrelvir) is a second-generation, orally bioavailable, SARS-CoV-2 main protease (Mpro) with Ki value of 2.48 nM, EC50 of 180 nM for inhibition of SARS-CoV-2 induced cytopathic effect (CPE).
PF-07817883 (Ibuzatrelvir) is a second-generation, orally bioavailable, SARS-CoV-2 main protease (Mpro) with Ki value of 2.48 nM, EC50 of 180 nM for inhibition of SARS-CoV-2 induced cytopathic effect (CPE).
PF-07817883 (Ibuzatrelvir) shows improved metabolic stability versus nirmatrelvir, the antiviral component of the ritonavir-boosted therapy Paxlovid.
PF-07817883 (Ibuzatrelvir) inhibits the SARS-CoV-1 Mpro (IC50 = 18 nM) and MERS Mpro (IC50 = 930 nM) activity, respectively, but has a much smaller disparity in the cell-based antiviral assays (SARS-CoV-1 EC50 = 157 nM and MERS EC50 = 158 nM).
PF-07817883 (Ibuzatrelvir) potently inhibits SARS-CoV-2 viral replication with EC50 and EC90 values of 34 nM and 70 nM respectively in Vero76 cells.
PF-07817883 (Ibuzatrelvir) also demonstrated oral efficacy in a mouse-adapted SARS-CoV-2 model at plasma concentrations equivalent to nirmatrelvir.
